Prostamax: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Prostamax is a short synthetic tetrapeptide (Lys-Glu-Asp-Pro; KEDP, CAS 473578-47-1) from the family of short-peptide bioregulators associated with the Khavinson group. It is investigated in preclinical models for its presumed prostatic tissue affinity and its proposed role as a regulator of gene expression. Independent evidence is limited. Material intended exclusively for research use.

Prostamax is a short-chain synthetic peptide with the sequence Lys-Glu-Asp-Pro (abbreviated KEDP), molecular formula C20H33N5O9, and a molecular weight of 487.51 g/mol (CAS 473578-47-1). It belongs to the category of the so-called short peptide bioregulators, a set of tetra-, tri-, and dipeptides developed and studied primarily by the group of Vladimir Khavinson at the Institute of Bioregulation and Gerontology in St. Petersburg. These compounds arose as "minimalist" synthetic versions inspired by peptide extracts from organs (the so-called cytomedins), with the hypothesis that very short peptide fragments could retain a supposed tissue specificity. In the case of Prostamax, the declared interest in that group's literature focuses on prostatic tissue, hence its research trade name. It is important to frame all of the above as material for exclusive use in laboratory research, not as a therapeutic agent.

From a structural standpoint, Prostamax is a linear tetrapeptide composed of lysine (K), glutamic acid (E), aspartic acid (D), and proline (P). Its small size and the presence of charged residues (one basic lysine versus two acidic residues, glutamate and aspartate) confer on it an amphoteric character and high solubility in aqueous medium. The C-terminal proline introduces a conformational constraint that may influence its resistance to some peptidases and its local folding. As is the case with most short-peptide bioregulators, its low molecular mass (below 500 Da) is a point that the developer group's literature has emphasized when proposing intracellular mechanisms of action, although independent and detailed pharmacokinetic characterization is scarce.

The proposed mechanism of action for Prostamax must be presented honestly about the level of evidence. The dominant hypothesis, formulated by the Khavinson group for this entire family of peptides, is that short peptides could cross cell and nuclear membranes and interact directly with DNA or chromatin, modulating the expression of tissue-specific genes. Within this framework, Prostamax has been proposed as a modulator of the activity of prostatic epithelial and stromal cells, with presumed effects on proliferation, differentiation, and markers of secretory function. A possible epigenetic action (interaction with promoter regions, changes in methylation state) and effects on tissue protein synthesis have also been posited. It should be emphasized that these mechanisms derive mostly from in vitro work and animal models generated by a single research group, and that there is no broad body of independent replication confirming direct peptide-DNA binding as a general phenomenon or its functional relevance in vivo. Therefore, any mechanistic description should be treated as a working hypothesis, not as an established fact.

As for documented research applications, Prostamax appears in the literature associated with exploratory studies on models of aging and of prostatic tissue function, within the broader program of "bioregulatory peptides" that encompasses analogs directed at different organs (for example, versions targeting thymus, liver, pineal, vessels, or cartilage). The described applications include: the study of the modulation of cell proliferation in prostatic tissue cultures, the evaluation of oxidative stress and senescence markers in experimental models, and the general interest in understanding whether short peptides can serve as research tools for modulating tissue gene expression. In the research context, Prostamax is usually used as a reagent to explore these hypotheses, and not as a compound with validated indications. No approved clinical use is attributed to it here.

The level of evidence is limited. Most of the publications on Prostamax and on the family of short bioregulation peptides come from the developer group itself, with relatively few independent trials, small samples, and a scarcity of rigorous clinical studies that are randomized and replicated by third parties. For a researcher this means that claims about tissue specificity, epigenetic mechanism, and functional effects must be treated with caution and verified experimentally before drawing conclusions from them. Human therapeutic efficacy should not be inferred from these preclinical data, nor should a complete safety profile be assumed. As with any poorly characterized research material, it is recommended to document the identity and purity of the lot (for example, by mass analysis and chromatography) before experimental use.

In summary, Prostamax is a short tetrapeptide (KEDP) of the peptide bioregulator class, with a hypothesized action centered on the genetic modulation of prostatic tissue and an evidence base that is still preliminary and concentrated in a single research lineage. Its current value is as a study tool in preclinical models, always under a strictly laboratory-research framework.